Press release from Companies
Published: 2025-09-19 08:30:00
Inhalation Sciences (ISAB) is pleased to announce the continued success and positive feedback from its recurring user base, this time it is a long-standing client, the University of Liège, following the publication of new research utilizing the PreciseInhale® platform.
The research, led by Professor Didier Cataldo, focused on the formulation and performance of a novel dry powder for inhalation, combining ciclesonide and indacaterol, two agents critical for treating asthma and chronic obstructive pulmonary disease (COPD). Over the course of one year, Professor Cataldo and his team have relied on PreciseInhale® to generate high-quality and reproducible data - data now central to their latest publication (see link below and attachment to this press release).
Reflecting on his experience with PreciseInhale®, Professor Cataldo stated:
“The PreciseInhale® system proved highly valuable for generating reproducible in vitro data on the aerosolization and lung deposition properties of our dry powder formulations. The platform allowed precise generation and characterization of respirable aerosols directly from small amounts of material, an important advantage when working with early-stage formulations. The system not only allowed prediction of regional lung deposition (particle size distribution, fine particle fraction) but also provided translationally relevant insights into powder performance by assessing powders’ aerosolization behaviour.”
The published study demonstrates that using PreciseInhale® enabled the team to compare the performance of their advanced carrier-free powder to leading commercial products, confirming superior fine particle fractions and lung deposition, even at lower flow rates. These findings support the role of innovative in vitro technologies in driving the next generation of pulmonary therapies.
“We are extremely proud to see PreciseInhale® at the heart of groundbreaking research at the University of Liège. Our goal has always been to provide scientists and clinicians with tools that deliver not just precision, but also true translational relevance. The positive feedback from Professor Cataldo and his team affirms our commitment to enabling the advancement of inhaled therapies”, says Manoush Masarrat, CEO of Inhalation Sciences.
The full publication, entitled Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying, can be accessed via the below link and is also attached to this press release.
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.
